↓ Skip to main content

Pain and dyspnea control during awake fiberoptic bronchoscopy in critically ill patients: safety and efficacy of remifentanil target-controlled infusion

Overview of attention for article published in Annals of Intensive Care, March 2021
Altmetric Badge

Mentioned by

twitter
2 tweeters
facebook
1 Facebook page

Readers on

mendeley
3 Mendeley
Title
Pain and dyspnea control during awake fiberoptic bronchoscopy in critically ill patients: safety and efficacy of remifentanil target-controlled infusion
Published in
Annals of Intensive Care, March 2021
DOI 10.1186/s13613-021-00832-6
Pubmed ID
Authors

Margot Caron, Antoine Parrot, Alexandre Elabbadi, Sophie Dupeyrat, Matthieu Turpin, Thomas Baury, Sacha Rozencwajg, Clarisse Blayau, Jean-Pierre Fulgencio, Aude Gibelin, Pierre-Yves Blanchard, Séverine Rodriguez, Daisy Daigné, Marie-Cécile Allain, Muriel Fartoukh, Tài Pham

Abstract

Flexible fiberoptic bronchoscopy is frequently used in intensive care unit, but is a source of discomfort, dyspnea and anxiety for patients. Our objective was to assess the feasibility and tolerance of a sedation using remifentanil target-controlled infusion, to perform fiberoptic bronchoscopy in awake ICU patients. This monocentric, prospective observational study was conducted in awake patients requiring fiberoptic bronchoscopy. In accordance with usual practices in our center, remifentanil target-controlled infusion was used under close monitoring and adapted to the patient's reactions. The primary objective was the rate of successful procedures without additional analgesia or anesthesia. The secondary objectives were clinical tolerance and the comfort of patients (graded from "very uncomfortable" to "very comfortable") and operators (numeric scale from 0 to 10) during the procedure. From May 2014 to December 2015, 72 patients were included. Most of them (69%) were hypoxemic and admitted for acute respiratory failure. No additional medication was needed in 96% of the patients. No severe side-effects occurred. Seventy-eight percent of patients described the procedure as "comfortable or very comfortable". Physicians rated their comfort with a median [IQR] score of 9 [8-10]. Remifentanil target-controlled infusion administered to perform awake fiberoptic bronchoscopy in critically ill patients is feasible without requirement of additional analgesics or sedative drugs. Clinical tolerance as well as patients' and operators' comfort were good to excellent. This technique could benefit patients' experience.

Twitter Demographics

The data shown below were collected from the profiles of 2 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 3 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 3 100%

Demographic breakdown

Readers by professional status Count As %
Researcher 3 100%
Readers by discipline Count As %
Medicine and Dentistry 2 67%
Nursing and Health Professions 1 33%

Attention Score in Context

This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 19 March 2021.
All research outputs
#13,396,399
of 17,468,018 outputs
Outputs from Annals of Intensive Care
#656
of 803 outputs
Outputs of similar age
#154,415
of 229,911 outputs
Outputs of similar age from Annals of Intensive Care
#1
of 1 outputs
Altmetric has tracked 17,468,018 research outputs across all sources so far. This one is in the 20th percentile – i.e., 20% of other outputs scored the same or lower than it.
So far Altmetric has tracked 803 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 13.4. This one is in the 14th percentile – i.e., 14% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 229,911 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 28th percentile – i.e., 28% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 1 others from the same source and published within six weeks on either side of this one. This one has scored higher than all of them